THC (tetrahydrocannabinol)– produces the “high” by increasing dopamine levels in the brain.

It is the chemical responsible for most of the psychological effects of cannabis. In fact, it acts much like the cannabinoid chemicals made naturally by the body. THC attaches to receptors in the brain and affects a person’s memory, pleasure, movements, thinking, concentration, coordination, and sensory and time perception by stimulating the brain to release dopamine.

THC increases appetite and reduces nausea. It may also decrease pain, inflammation (swelling and redness) and muscle control problems, and can induce feelings of relaxation. It also can affect motor coordination and cognitive performance.

It is shown to have therapeutic benefits in treating:

  • Pain
  • PTSD
  • Nausea/vomiting
  • Anorexia
  • Asthma
  • Glaucoma pain
  • Insomnia
  • Spasticity
  • Epilepsy
  • Dependency and withdrawal
  • Psychiatric symptoms
  • Autoimmune diseases and inflammation
  • Tinnitus
  • Chronic fatigue

CBD (cannabidiol) – Produces little or no “high,” counteracts high and sleepiness when combined with THC.

CBD is a cannabinoid that does not affect the mind or behavior. It has been shown to be useful in reducing pain and inflammation, controlling epileptic seizures, and possibly even treating mental illness and addictions.

There is growing interest in using CBD to treat certain conditions such as childhood epilepsy, a disorder that causes a child to have violent seizures. Therefore, scientists have been cultivating cannabis plants and making CBD in oil form for treatment purposes. (Nevada Botanical Science creates medical cannabis using the oil method.2

It is shown to have therapeutic benefits in treating:

  • Seizure activity
  • Anxiety
  • Inflammation
  • Tumors/Cancer
  • Chronic pain
  • Nausea
  • Rheumatoid arthritis
  • Schizophrenia
  • Diabetes
  • PTSD
  • Alcoholism
  • Strokes
  • Cardiovascular disease



2 Pharmacol Res. 2016 Mar 11;107:85-92. doi: 10.1016/j.phrs.2016.03.005. [Epub ahead of print]

Cannabidiol and epilepsy: Rationale and therapeutic potential.

Leo A1, Russo E1, Elia M2.


Pharmacol Res. 2016 Feb 1. pii: S1043-6618(16)00039-6. doi:

Cannabidiol, neuroprotection and neuropsychiatric disorders.

Campos AC, Fogaça MV, Sonego AB, Guimarães FS.


Curr Pain Headache Rep. 2015 Oct;19(10):50. doi: 10.1007/s11916-015-0524-x.

Medical Marijuana and Chronic Pain: a Review of Basic Science and Clinical Evidence.

Jensen B1, Chen J, Furnish T, Wallace M.


J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28.The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids. McAllister SD, Soroceanu L, Desprez PY.


Neuropharmacology. 2005 Jun;48(8):1117-29. Epub 2005 Apr 26.

Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors.Fride E1, Ponde D, Breuer A, Hanus L


Expert Rev Neurother. 2014 Dec;14(12):1453-65. doi: 10.1586/14737175.2014.985209.

Medical marijuana in neurology.Benbadis SR1, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson D, Vu T, Smith A, Zesiewicz T.


J Pain. 2015 Jul;16(7):616-27. doi: 10.1016/j.jpain.2015.03.008. Epub 2015 Apr 3.

Efficacy of Inhaled Cannabis on Painful Diabetic Neuropathy.

Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH.